



Centre for  
Public Health

# **Merseyside Inter Agency Drug Misuse Database**

January - March 2010

**Halton DAAT**

Quarter 4 2009/10

**Lloyd Baron, Steven Griffith,  
Martin Chandler, Jim McVeigh**

DRAFT REPORT

The final version will be available on the IAD website

[www.cph.org.uk/iad](http://www.cph.org.uk/iad)

Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Ellie McCoy and Paul Duffy.

We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:

Martin Chandler  
IAD Manager  
Centre for Public Health  
Faculty of Health & Applied Social Sciences  
Liverpool John Moores University  
4th Floor, Kingsway House  
Hatton Gardens  
Liverpool  
L3 2AY

(0151) 904 6031

[m.chandler@ljamu.ac.uk](mailto:m.chandler@ljamu.ac.uk)

Lloyd Baron  
IAD Researcher

(0151) 231 8014

[L.R.Baron@ljamu.ac.uk](mailto:L.R.Baron@ljamu.ac.uk)

[www.cph.org.uk/iad](http://www.cph.org.uk/iad)

## Contents

	<b>Page</b>
<b>Introduction</b>	<b>1</b>
<b>Arrest Referral</b>	<b>3</b>
Table 1: Arrest Referral Current Quarter; Individuals assessed, by Gender and Age Group	
Table 2: Arrest Referral Year to Date; by Gender and Age Group	
Table 3: Arrest Referral Current Quarter; Individuals assessed, by Gender & Age Group - Halton Residents Only	
Table 4: Arrest Referral Current Quarter; Reported Main Drug(s) of Use, by Frequency of Use	
<b>Probation</b>	<b>5</b>
Table 5: Probation Current Quarter; Probation clients by Gender and Age Group	
Table 6: Probation Year to Date, by Gender and Age Group	
Table 7: Probation Current Quarter; Reported Main Drug(s) of Use, by Frequency of Use	
Current Quarter ASROs	
Fig 1: Current Quarter Crossover between Probation Individuals and NDTMS Datasets	
<b>Needle and Syringe Programmes (NSPs)</b>	<b>7</b>
<b>Agency</b>	
Table 8: Agency NSP Current Quarter; Individuals by Gender	
Table 9: Agency NSP Current Quarter; Individuals by Gender: Steroid Users omitted	
Table 10: Agency NSP Current Quarter; Individuals by Age Group	
Table 11: Agency NSP Current Quarter; Individuals by Age Group: Steroid Users omitted	
Table 12: Agency NSP Current Quarter; Gender by Age Group of Individuals	
Table 13: Agency NSP Current Quarter; Gender by Age Group: Steroid Users omitted	
Table 14: Agency NSP Year to Date, by Gender & Age Group	
Table 15: Agency NSP Year to Date, by Gender & Age Group: Steroid Users Omitted	
Table 16: Current Quarter; Main Drug of Use for New NSP Clients, by Gender	
Table 17: Current Quarter; Main Drug of Use for All NSP Clients, by Gender	
Table 18: Current Quarter; Main Drug of Use, for New NSP Clients, by Age Group	
Table 19: Current Quarter; NSP Clients, by Data Source	
Table 20: Current Quarter; NSP Clients, Attributable and Non Attributable Data	

**Pharmacy** **13**

- Table 21: Pharmacy NSP Current Quarter; Individuals by Gender
- Table 22: Pharmacy NSP Current Quarter; Individuals by Age Group
- Table 23: Year to Date, by Gender & Age Group
- Table 24: Current Quarter; Individuals by Pharmacy NSP Site
- Table 25: Current Quarter; Transactions by Pharmacy NSP Site

**Combined** **15**

- Table 26: Current Quarter; Individuals in Agency and Pharmacy NSP, by Gender
- Table 27: Current Quarter; Individuals in Agency and Pharmacy NSP, by Gender: Steroid Users omitted
- Table 28: Current Quarter; Individuals in Agency and Pharmacy NSP, by Age Group
- Table 29: Current Quarter; Individuals in Agency and Pharmacy NSP, by Age Group: Steroid Users omitted
- Table 30: Year to Date, by Gender & Age Group
- Table 31: Combined Pharmacy and Agency NSP Total Syringes Provided

**National Drug Treatment Monitoring System (NDTMS)** **18**

- Table 32: NDTMS Current Quarter; Individuals in contact with Treatment Services, by Gender
- Table 33: Year to Date, by Gender
- Table 34: NDTMS Current Quarter; Individuals in contact with Treatment Services, by Age Group
- Table 35: Year to Date, by Age Group
- Table 36: NDTMS Current Quarter; Individuals Reporting Alcohol as Primary substance and Amphetamine/Opiate/Crack as Secondary Substance
- Table 37: NDTMS Current Quarter; Ethnicity of Individuals in Contact with Treatment Services
- Table 38: NDTMS Current Quarter; Individuals in contact with Treatment Services, by Main Drug of Use

<b>Addaction Outreach</b>	<b>22</b>
Table 39: Addaction Individuals by Gender	
Table 40: Year to Date, by Gender	
Table 41: Addaction Clients Main drug by age Group	
<b>Connexions</b>	<b>23</b>
Table 42: Connexions Current Quarter; Individuals in Contact with Connexions, by Gender	
Table 43: Year to Date, by Gender	
Table 44: Connexions Current Quarter; Individuals in Contact with Connexions, by Age	
Table 45: Year to Date, by Age	
Table 46: Connexions Current Quarter; Individuals in Contact with Connexions by Drug/Alcohol Problem	
Table 47: Year to Date, by Drug /Alcohol Problem	
<b>Combined Datasets</b>	<b>25</b>
Table 48: Current Quarter; Total Problem Drug Users reported to the IAD, by Gender and Age Group	
Table 49: Year to Date Problem Drug Users, by Gender & Age Group	
<b>Cross Matched Datasets</b>	<b>26</b>
Fig 2: Crossover between Agency NSP and NDTMS datasets	
Fig 3: Crossover between Pharmacy NSP and NDTMS datasets	
Fig 4: Crossover between YTD Agency NSP and NDTMS datasets	
Fig 5: Crossover between YTD Pharmacy NSP and NDTMS datasets	

## Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle and syringe programmes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

### Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.



The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

**ARREST REFERRAL (AR)**

Quarter 4 (2009/10)

**Introduction**

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

**NOTE:** Table 3 figures are based on DAT of Residence, NOT DAT of contact as with all other Arrest Referral data.

**Table 1: Arrest referral Current Quarter; Individuals assessed, by Gender & Age Group**

Gender	n	%
Male	8	100.0
Female	0	0.0
Age Group		
Under 18	0	0.0
18-19	0	0.0
20-24	2	25.0
25-29	0	0.0
30-34	3	37.5
35-39	1	12.5
40-44	0	0.0
45+	2	25.0
<b>Total</b>	8	100

**Table 2: Arrest Referral Year to Date ; by Gender & Age Group**

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	0	0.0	0	0.0	0	0.0
18-19	1	2.9	0	0.0	1	2.7
20-24	7	20.0	0	0.0	7	18.9
25-29	8	22.9	0	0.0	8	21.6
30-34	6	17.1	0	0.0	6	16.2
35-39	6	17.1	2	100.0	8	21.6
40-44	4	11.4	0	0.0	4	10.8
45+	3	8.6	0	0.0	3	8.1
<b>Total</b>	35	100	2	100	37	100

**Table 3: Arrest Referral Current Quarter; Individuals assessed, by Gender & Age Group - Halton Residents Only (Includes clients seen in other DA(A)T areas)**

Gender	n	%
Male	14	100.0
Female	0	0.0
Age Group		
Under 18	0	0.0
18-19	0	0.0
20-24	3	21.4
25-29	2	14.3
30-34	3	21.4
35-39	2	14.3
40-44	2	14.3
45+	2	14.3
<b>Total</b>	14	100

**Table 4: Arrest Referral Current Quarter; Reported Main Drug(s)\* of Use, by Frequency of Use**

Drug of Use	Daily	Weekly	Monthly
Amphetamines	-	-	-
Benzodiazepines	-	-	-
Cannabis	1	0	0
Crack	-	-	-
Cocaine	0	2	0
Ecstasy	-	-	-
Heroin	2	1	1
Methadone	-	-	-
Other	1	0	0

**2 individuals did not report a main drug of use**

**NB:** The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

## PROBATION

### Quarter 4 (2009/10)

#### Introduction

Data is provided by Cheshire Probation Services. Data relates to individuals reported through OASys with a reported substance use problem. Individuals who are on ASROs or similar treatment orders are reported to NDTMS.

**NOTE:** Probation figures are based on DAT of Residence, NOT DAT of contact as with other datasets.

**Table 5: Probation Current Quarter; Probation Clients by Gender and Age Group**

Gender	n	%
Male	82	91.1
Female	8	8.9
Age Group		
Under 18	0	0.0
18-19	5	5.6
20-24	23	25.6
25-29	20	22.2
30-34	11	12.2
35-39	13	14.4
40-44	9	10.0
45+	9	10.0
<b>Total</b>	90	100

**Table 6: Probation Year to Date, by Gender & Age Group**

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	31	10.0	3	6.7	34	9.6
20-24	75	24.2	9	20.0	84	23.7
25-29	60	19.4	5	11.1	65	18.3
30-34	35	11.3	9	20.0	44	12.4
35-39	38	12.3	5	11.1	43	12.1
40-44	38	12.3	6	13.3	44	12.4
45+	33	10.6	8	17.8	41	11.5
<b>Total</b>	310	100	45	100	355	100

**Table 7: Probation Current Quarter; Reported Main Drug(s) of Use, by Frequency of Use**


Drug of Use	Daily	Weekly
Amphetamines	1	0
Benzodiazepines	0	1
Cannabis	13	4
Crack	3	1
Cocaine	1	1
Ecstasy	0	0
Heroin	5	1
Methadone	1	0
Prescription Drugs	0	0
Other	0	0

N.B: Table 7 shows the number of people reporting daily or weekly use of specific drugs. This is to reflect reporting of polydrug use through Probation data. No totals are given as clients can report daily or weekly use of more than one drug and may therefore be double counted between drugs.

**Current Quarter; ASROs**

- 0 ASROs were commenced during Q4
- 0 Individuals commenced ASROs during Q4
- 9 ASROs were terminated during Q4
- 6 Individuals had their ASROs terminated during Q4

**Fig 1: Current Quarter Crossover between Probation Individuals and NDTMS Datasets**



## NEEDLE AND SYRINGE PROGRAMMES

Quarter 4 (2009/10)

### Introduction

Data are collected directly from needle and syringe programmes (NSPs). Analysis of NSP data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

### AGENCY NSP

**Table 8: Agency NSP Current Quarter; Individuals by Gender**

New Clients	n	%
Male	55	100
Female	0	0.0
<b>Total</b>	55	100
All Clients		
Male	205	95.8
Female	9	4.2
<b>Total</b>	214	100

**Table 9: Agency NSP Current Quarter; Individuals by Gender: Steroids Users Omitted**

New Clients	n	%
Male	6	100.0
Female	0	0.0
<b>Total</b>	6	100
All Clients		
Male	42	84.0
Female	8	16.0
<b>Total</b>	50	100

Table 10: Agency NSP Current Quarter; Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	1	1.8	1	<1
18-19	4	7.3	4	1.9
20-24	19	34.5	50	23.4
25-29	11	20.0	44	20.6
30-34	9	16.4	44	20.6
35-39	3	5.5	31	14.5
40-44	6	10.9	26	12.1
45+	2	3.6	14	6.5
<b>Total</b>	55	100	214	100

Table 11: Agency NSP Current Quarter; Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	1	16.7	4	8.0
25-29	0	0.0	3	6.0
30-34	2	33.3	11	22.0
35-39	0	0.0	12	24.0
40-44	2	33.3	13	26.0
45+	1	16.7	7	14.0
<b>Total</b>	6	100	50	100

**Table 12: Agency NSP Current Quarter; Gender by Age Group of Individuals**

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	1	<1	0	0.0
18-19	4	2.0	0	0.0
20-24	49	23.9	1	11.1
25-29	44	21.5	0	0.0
30-34	43	21.0	1	11.1
35-39	28	13.7	3	33.3
40-44	25	12.2	1	11.1
45+	11	5.4	3	33.3
<b>Total</b>	205	100	9	100

**Table 13: Agency NSP Current Quarter; Gender by Age Group: Steroid Users Omitted**

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	3	7.1	1	12.5
25-29	3	7.1	0	0.0
30-34	10	23.8	1	12.5
35-39	9	21.4	3	37.5
40-44	12	28.6	1	12.5
45+	5	11.9	2	25.0
<b>Total</b>	42	100	8	100

Table 14: Agency NSP Year to Date, by Gender &amp; Age Group

	Gender				<i>Total in Age Group</i>	
	Male		Female			
<b>Age Group</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
Under 18	1	<1	0	0.0	1	<1
18-19	10	1.9	3	8.3	13	2.3
20-24	128	24.3	11	30.6	139	24.7
25-29	131	24.9	6	16.7	137	24.4
30-34	103	19.6	3	8.3	106	18.9
35-39	72	13.7	4	11.1	76	13.5
40-44	46	8.7	1	2.8	47	8.4
45+	35	6.7	8	22.2	43	7.7
<b>Total</b>	526	100	36	100	562	100

Table 15: Agency NSP Year to Date, by Gender &amp; Age Group: Steroid Users Omitted

	Gender				<i>Total in Age Group</i>	
	Male		Female			
<b>Age Group</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
Under 18	0	0.0	0	0.0	0	0.0
18-19	1	1.0	3	8.6	4	3.0
20-24	12	12.1	11	31.4	23	17.2
25-29	13	13.1	6	17.1	19	14.2
30-34	24	24.2	3	8.6	27	20.1
35-39	19	19.2	4	11.4	23	17.2
40-44	16	16.2	1	2.9	17	12.7
45+	14	14.1	7	20.0	21	15.7
<b>Total</b>	99	100	35	100	134	100

Table 16: Current Quarter; Main Drug of Use for New Agency NSP Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	3	5.5	0	0.0
Methadone	2	3.6	0	0.0
Steroids	49	89.1	0	0.0
Morphine	1	1.8	0	0.0
Unknown	0	0.0	0	0.0
<b>Total</b>	55	100	0	0

Table 17: Current Quarter; Main Drug of Use for All NSP Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	1	11.1
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	25	12.2	4	44.4
Methadone	3	1.5	1	11.1
Morphine	2	1.0	0	0.0
Steroids	163	79.5	1	11.1
Various	5	2.4	1	11.1
Other	0	0.0	1	11.1
Unknown	7	3.4	0	0.0
<b>Total</b>	205	100	9	100

**Current Quarter; Melanotan Clients**

- 0 New Male clients reported using melanotan during Q4
- 0 New Female clients reported using melanotan during Q4
- 0 Male clients reported using melanotan during Q4
- 1 Female clients reported using melanotan during Q4

**Table 18: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group**

Age Group	Ampheta- mine		Cocaine		Heroin		Methadone		Steroids		Unknown	
	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	-	-	-	-	0	0.0	0	0.0	1	2.0	-	-
18-19	-	-	-	-	0	0.0	0	0.0	4	8.2	-	-
20-24	-	-	-	-	1	33.3	0	0.0	18	36.7	-	-
25-29	-	-	-	-	0	0.0	0	0.0	11	22.4	-	-
30-34	-	-	-	-	1	33.3	1	50.0	7	14.3	-	-
35-39	-	-	-	-	0	0.0	0	0.0	3	6.1	-	-
40-44	-	-	-	-	1	33.3	1	50.0	4	8.2	-	-
45+	-	-	-	-	0	0.0	0	0.0	1	2.0	-	-
<b>Total</b>	-	-	-	-	3	100	2	100	49	100	-	-

\* % Totals are by drug, not Age Group

**Please Note:** Due to a change in reporting methods main drug of use by age group will only be reported for new clients. Information on age group for all clients is available on request.

**Table 19: Current Quarter; Agency Syringe Exchange Clients, by Data Source**

All Clients	n	%
Halton DDC	209	97.6
Addaction Outreach	5	2.4
<b>Total</b>	214	100

**Table 20: Current Quarter; Agency Syringe Exchange Clients, Attributable and Non Attributable Data Halton DDC transactions Only**

All Clients	n	%
Attributable Data	304	99.3
Non-Attributable Data	2	0.7
<b>Total</b>	306	100

## PHARMACY NSPs

Table 21: Pharmacy NSP Current Quarter; Individuals by Gender

New Clients	n	%
Male	13	81.3
Female	3	18.7
<b>Total</b>	16	100
All Clients		
Male	29	87.9
Female	4	12.1
<b>Total</b>	33	100

Table 22: Pharmacy NSP Current Quarter; Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	2	12.5	3	9.1
25-29	3	18.8	3	9.1
30-34	3	18.8	9	27.3
35-39	2	12.5	4	12.1
40-44	5	31.3	12	36.4
45+	1	6.3	2	6.1
<b>Total</b>	16	100	33	100

Table 23: Year to Date, by Gender &amp; Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	1	<1	0	0.0	1	<1
20-24	10	8.7	0	0.0	10	7.7
25-29	23	20.0	1	6.7	24	18.5
30-34	26	22.6	4	26.7	30	23.1
35-39	18	15.7	8	53.3	26	20.0
40-44	22	19.1	2	13.3	24	18.5
45+	15	13.0	0	0.0	15	11.5
<b>Total</b>	115	100	15	100	130	100

**Table 24: Pharmacy NSP Current Quarter; Individuals by Pharmacy Site**

<b>All Clients</b>	<b>n</b>	<b>%</b>
Superdrug Runcorn	0	0.0
Castlefield Health Centre Runcorn	0	0.0
Co-op Albert Road Widnes	0	0.0
Lloyds Albert Road Widnes	33	100
Co-op Peelhouse Lane Widnes	0	0.0
<b>Total</b>	33	100

**Table 25: Pharmacy NSP Current Quarter; Transactions by Pharmacy Site**

<b>All Transactions</b>	<b>n</b>	<b>%</b>
Superdrug Runcorn	0	0.0
Castlefield Health Centre Runcorn	0	0.0
Co-op Albert Road Widnes	0	0.0
Lloyds Albert Road Widnes	68	100
Co-op Peelhouse Lane Widnes	0	0.0
<b>Total</b>	68	100

## COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

**Table 26: Current Quarter; Individuals in Agency and Pharmacy NSP, by Gender**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	67	95.7
Female	3	4.3
<b>Total</b>	70	100
<b>All Clients</b>		
Male	227	94.6
Female	13	5.4
<b>Total</b>	240	100

**Table 27: Current Quarter; Individuals in Agency and Pharmacy NSP, by Gender: Steroid Users Omitted\***

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	18	85.7
Female	3	14.3
<b>Total</b>	21	100
<b>All Clients</b>		
Male	64	84.2
Female	12	15.8
<b>Total</b>	76	100

\*Only known steroid users, based on Agency NSP data, have been omitted.

Table 28: Current Quarter; Individuals in Agency and Pharmacy NSP , by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	1	1.4	1	<1
18-19	4	5.7	4	1.7
20-24	21	30.0	53	22.1
25-29	14	20.0	47	19.6
30-34	12	17.1	51	21.3
35-39	5	7.1	34	14.2
40-44	10	14.3	34	14.2
45+	3	4.3	16	6.7
<b>Total</b>	70	100	240	100

Table 29: Current Quarter; Individuals in Agency and Pharmacy NSP, by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	3	14.3	7	9.2
25-29	3	14.3	6	7.9
30-34	5	23.8	18	23.7
35-39	2	9.5	15	19.7
40-44	6	28.6	21	27.6
45+	2	9.5	9	11.8
<b>Total</b>	21	100	76	100

Table 30: Year to Date, by Gender &amp; Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	1	<1	0	0.0	1	<1
18-19	11	1.8	3	6.0	14	2.1
20-24	135	21.8	11	22.0	146	21.9
25-29	153	24.8	7	14.0	160	24.0
30-34	121	19.6	6	12.0	127	19.0
35-39	87	14.1	12	24.0	99	14.8
40-44	63	10.2	3	6.0	66	9.9
45+	47	7.6	8	16.0	55	8.2
<b>Total</b>	618	100	50	100	668	100

Table 31: Combined Pharmacy and Agency NSP Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	10,916	549	11,465	46,968

**NB:** We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

## National Drug Treatment Monitoring System (NDTMS) Quarter 4 (2009/10)

### Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

### New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

**Table 32: NDTMS Current Quarter; Individuals in Contact with Treatment Services, by Gender**

<b>New Clients</b>	n	%
Male	56	77.8
Female	16	22.2
<b>Total</b>	72	100
<b>All Clients</b>		
Male	550	72.8
Female	206	27.2
<b>Total</b>	756	100

**Table 33: Year to Date, by Gender**

<b>New Clients</b>	n	%
Male	196	78.1
Female	55	21.9
<b>Total</b>	251	100
<b>All Clients</b>		
Male	555	72.8
Female	207	27.2
<b>Total</b>	762	100

**Table 34: NDTMS Current Quarter; Individuals in Contact with Treatment Services, by Age Group**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	9	12.5	59	7.8
18-19	1	1.4	27	3.6
20-24	12	16.7	98	13.0
25-29	9	12.5	135	17.9
30-34	19	26.4	165	21.8
35-39	12	16.7	141	18.7
40-44	2	2.8	68	9.0
45+	8	11.1	63	8.3
<b>Total</b>	72	100	756	100

**Table 35: Year to Date, by Age Group**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	27	10.8	59	7.7
18-19	6	2.4	28	3.7
20-24	42	16.7	98	12.9
25-29	37	14.7	136	17.8
30-34	51	20.3	167	21.9
35-39	41	16.3	141	18.5
40-44	21	8.4	73	9.6
45+	26	10.4	60	7.9
<b>Total</b>	251	100	762	100

**Table 36: NDTMS Current Quarter; Individuals Reporting Alcohol as Primary substance and Amphetamine/Opiate/Crack as Secondary Substance**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	0	0.0
Female	0	0.0
<b>Total</b>	-	-

**Table 37: NDTMS Current Quarter; Ethnicity of Individuals in Contact with Treatment Services**

<b>Ethnicity</b>	<b>New Clients</b>		<b>All Clients</b>	
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
White British	72	100.0	748	98.9
White Irish	0	0.0	0	0.0
Other White	0	0.0	1	<1
White & Black Caribbean	0	0.0	2	<1
White & Asian	0	0.0	0	0.0
Other Asian	0	0.0	0	0.0
Caribbean	0	0.0	3	<1
Chinese	0	0.0	0	0.0
Other	0	0.0	0	0.0
Unknown	0	0.0	2	<1
<b>Total</b>	72	100	756	100

**Table 38: NDTMS Current Quarter; Individuals in Contact with Treatment Services, by Main Drug of Use**

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	27	37.5	397	52.5
Methadone	3	4.2	59	7.8
Other Opiates	1	1.4	15	2.0
Benzodiazepines	1	1.4	2	<1
Amphetamines	1	1.4	12	1.6
Cocaine	13	18.1	98	13.0
Crack	2	2.8	21	2.8
Hallucinogens	0	0.0	0	0.0
Ecstasy	0	0.0	0	0.0
Cannabis	23	31.9	140	18.5
Antidepressants	0	0.0	1	<1
Prescription Drugs	1	1.4	8	1.1
Other/Unknown	0	0.0	3	<1
<b>Total</b>	<b>72</b>	<b>100</b>	<b>756</b>	<b>100</b>

## ADDACTION OUTREACH

Quarter 4 (2009/10)

### Background

Addaction Outreach Service offers a confidential service throughout the Halton area for adult clients in need of support around substance misuse. The service offers a mobile needle exchange and advice and information as well as harm reduction advice is provided. Addaction provides data presented here.

**Table 39: Addaction Individuals by Gender**

New Clients	n	%
Male	1	100
Female	0	0.0
<b>Total</b>	<b>1</b>	<b>100</b>
All Clients		
Male	4	80.0
Female	1	20.0
<b>Total</b>	<b>5</b>	<b>100</b>

**Table 40: Year to Date, by Gender**

All Clients	n	%
Male	22	78.6
Female	6	21.4
<b>Total</b>	<b>28</b>	<b>100</b>

**Table 41: Addaction Clients Main Drug by Age Group**

Age Group	Ampheta- mine		Benzodi- azepine		Crack		Heroin		Methadone		Melanotan		Steroids	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	-	-	-	-	-	-	-	-	0	0.0	-	-	-	-
18-19	-	-	-	-	-	-	-	-	0	0.0	-	-	-	-
20-24	-	-	-	-	-	-	-	-	0	0.0	-	-	-	-
25-29	-	-	-	-	-	-	-	-	0	0.0	-	-	-	-
30-34	-	-	-	-	-	-	-	-	1	20.0	-	-	-	-
35-39	-	-	-	-	-	-	-	-	2	40.0	-	-	-	-
40-44	-	-	-	-	-	-	-	-	2	40.0	-	-	-	-
45+	-	-	-	-	-	-	-	-	0	0.0	-	-	-	-
<b>Total*</b>	-	-	-	-	-	-	-	-	5	100	-	-	-	-

\*% Totals are by drug, not Age Group

## CONNEXIONS

### Quarter 4 (2009/10)

#### Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

**Table 42: Connexions Current Quarter; Individuals in Contact with Connexions, by Gender**

Gender	n	%
Male	26	76.5
Female	8	23.6
<b>Total</b>	34	100

**Table 43: Year to Date, by Gender**

Gender	n	%
Male	34	65.4
Female	18	34.6
<b>Total</b>	52	100

**Table 44: Connexions Current Quarter; Individuals in Contact with Connexions, by Age**

Age Group	n	%
16	8	23.5
17	10	29.4
18	6	17.6
19	10	29.4
<b>Total</b>	34	100

**Table 45: Year to Date, by Age**

Age Group	n	%
16	9	17.3
17	13	25.0
18	14	26.9
19	16	30.8
<b>Total</b>	52	100

**Table 46: Connexions Current Quarter; Individuals in Contact with Connexions by Drug/Alcohol Problem**

<b>Substance</b>	<b>n</b>	<b>%</b>
Alcohol/Other*	6	17.6
Drugs	28	82.4
<b>Total</b>	<b>34</b>	<b>100</b>

\*"Other" is generally used to refer to solvents although this is not necessarily always the case.

**Table 47: Year to Date, by Drug/Alcohol problem**

<b>Substance</b>	<b>n</b>	<b>%</b>
Alcohol/Other*	12	23.1
Drugs	40	76.9
<b>Total</b>	<b>52</b>	<b>100</b>

\*"Other" is generally used to refer to solvents although this is not necessarily always the case.

## COMBINED DATASETS

Quarter 4 (2009/10)

### Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Needle and Syringe Programmes (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

**Table 48: Total Problem Drug Users reported to the IAD, by Gender and Age Group**

Gender	n	%
Male	830	78.7
Female	224	21.3
Age Group		
Under 18	76	7.2
18-19	46	4.4
20-24	171	16.2
25-29	195	18.5
30-34	208	19.7
35-39	173	16.4
40-44	102	9.7
45+	83	7.9
<b>Total</b>	1,054	100

**Table 49: Year to Date, by Gender and Age Group**

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	70	5.0	11	3.7	81	4.7
18-19	72	5.1	27	9.0	99	5.8
20-24	272	19.3	43	14.4	315	18.4
25-29	281	19.9	52	17.4	333	19.5
30-34	240	17.0	64	21.4	304	17.8
35-39	219	15.5	47	15.7	266	15.6
40-44	145	10.3	22	7.4	167	9.8
45+	111	7.9	33	11.0	144	8.4
<b>Total</b>	1,410	100	299	100	1,709	100

**CROSS-MATCHED DATASETS**


Quarter 4 (2009/10)

Data are shown for the crossover between each type of Needle and Syringe Programme and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.


For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of needle and syringe programme site.


**Fig 2: Current Quarter Crossover between Agency NSP and NDTMS datasets**



**Fig 3: Current Quarter Crossover between Pharmacy NSP and NDTMS Datasets**



**Fig 4: Year to Date Crossover between Agency NSP and NDTMS datasets**



**Fig 5: Year to Date Crossover between Pharmacy NSP and NDTMS datasets**

